
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
SASY | Paris | EUR | Real-time | |
SANp | BATS Europe | EUR | Delayed | |
SNY | NASDAQ | USD | Real-time | |
0O59 | London | EUR | Real-time | |
SNYN | Mexico | MXN | Delayed | |
SANF | Milan | EUR | Real-time | |
SASY | TradeGate | EUR | Delayed | |
SASY | Xetra | EUR | Delayed | |
SASY | Frankfurt | EUR | Delayed |
By John Miller ZURICH (Reuters) - The World Health Organization on Tuesday recommended using arthritis drugs Actemra from Roche and Kevzara from Sanofi (PA:SASY) with corticosteroids for COVID-19...
(Makes clear investment figure is annual sum) PARIS (Reuters) -Sanofi will invest about 400 million euros ($476 million) annually in research and development of next-generation vaccines using mRNA...
BRUSSELS (Reuters) - Belgian agri-tech company Biotalys announced on Tuesday plans to list on Euronext Brussels in the coming weeks, hoping to entice investors with its biological alternatives to...
(Refiles to change word in headline) By Jeff Mason and Carl O'Donnell WASHINGTON (Reuters) -The White House laid out a plan for the United States to share 25 million surplus COVID-19 vaccine doses to...
By Dhirendra Tripathi Investing – Merck (NYSE:MRK) shares rose 1% Thursday ahead of the day’s listing of Organon (NYSE:OGN_w), its spun-off business that has a broad portfolio of...
By Dominique Vidalon PARIS (Reuters) -France's Sanofi (PA:SASY) and Britain's GlaxoSmithKline launched a late-stage human trial for a recombinant COVID-19 vaccine candidate on Thursday which they...
By Sabine Siebold and Francesco Guarascio BRUSSELS (Reuters) - The European Union expects to have received more than a billion doses of COVID-19 vaccines by the end of September from four drugmakers,...
By Agnieszka Barteczko, Anna Koper and Michael Kahn WARSAW/PRAGUE (Reuters) - In the race to supply vaccines to end the COVID-19 pandemic, U.S. drug developer Novavax turned to emerging Europe to...
By Matthias Blamont PARIS (Reuters) -An experimental COVID-19 vaccine developed by Sanofi (PA:SASY) and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling...
By Alistair Smout LONDON (Reuters) - A second-generation COVID-19 vaccine developed by CureVac and GlaxoSmithKline, designed to protect against coronavirus variants, produced a high level of immune...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review